McKesson stock has delivered a very strong 336.0% return over the past five years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) model both still point to the shares trading below their estimated worth. Over 5 years, McKesson has returned 336.0%, which puts recent share price moves in the context of a long and very strong run. Expectations for McKesson's ability to keep converting revenue into reliable cash flows can support the...

McKesson (MCK) is in focus after its technology leadership team joined the 17th Annual Atlanta C-Level Technology Leadership Summit, highlighting how its healthcare technology services fit alongside recent quarterly results and the current stock performance. See our latest analysis for McKesson. At a share price of $853.71, McKesson has eased slightly in the very short term, with a 1-day share price return that declined 1.79% and a 7-day share price return that declined 2.85%. However, its...

Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.

Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare providers & services stocks fared in Q2, starting with McKesson (NYSE:MCK).

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment. For the q

S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.

QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.

ITGR beats Q2 earnings and revenue estimates, but sales and margins decrease as product headwinds persist ahead of its $5.7B KKR deal.

McKesson (NYSE:MCK) reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum across its operating businesses and prompting the healthcare services company to raise its full-year adjusted earnings outlook. Revenue rose 8% to $105.4 billion, while adjuste

On August 5, 2026, McKesson Corporation reported first-quarter fiscal 2027 results showing sales of US$105.38 billion, higher than a year earlier, while net income and earnings per share from continuing operations declined year-on-year. Alongside these results, McKesson completed a large portion of its long-running share repurchase program and raised adjusted earnings guidance, highlighting management’s confidence in specialty and oncology growth, technology and AI investments, and the...

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.

TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.

RGTI's Q2 revenues surge 185.3% and beat estimates, but widening losses and higher R&D and SG&A costs continue to pressure profitability.

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.

PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.

McKesson raises fiscal 2027 earnings guidance after pharma profit rises 19%, while specialty demand, oncology growth and disciplined spending shape the call.

McKesson Corp (MCK) delivered an 8% revenue increase to $105.4 billion and a 20% adjusted EPS surge, prompting a full-year guidance raise and a 15% dividend boost.

McKesson (MCK) delivered earnings and revenue surprises of +5.19% and +0.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain.

Healthcare distributor and services company McKesson (NYSE:MCK) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.7% year on year to $105.4 billion. Its non-GAAP profit of $9.93 per share was 4.1% above analysts’ consensus estimates.

TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.

Hinge Health's Q2 revenues jump 53% as stronger member yield, margin gains and raised 2026 guidance reinforce business momentum.

Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

The benchmark US stock measures were trending higher in Wednesday's premarket activity amid growing

Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.

McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.

BrightSpring's 18.1% weekly slide clashes with strong growth and raised guidance as valuation, policy and integration risks test the rebound case.

INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.

McKesson heads into Q1 with AI-driven efficiency, specialty momentum and oncology growth in focus as pricing dynamics may temper revenues.

BTSG's Q2 earnings and revenues beat estimates as pharmacy and provider growth drive margin gains and a higher 2026 outlook.

McKesson, Encompass Health and Omega Healthcare Investors raised dividends, with payout ratios and yields showing varying levels of sustainability across the healthcare sector.

A weekly roundup covering Magnificent Seven earnings, Fed rate pauses, U.S.-Iran tensions, and MarketBeat analysts' takes on stocks including Microsoft, Alphabet, Broadcom, Tesla, and UnitedHealth.

DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.

Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.

Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.

Get a deeper insight into the potential performance of McKesson (MCK) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

In the most recent trading session, McKesson (MCK) closed at $865.51, indicating a -2.59% shift from the previous trading day.